| General Information of Drug Metabolite (DM) (ID: DM001467) |
| DM Name |
AP26123
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C8 (CYP2C8)
|
DME0018
|
| Multi-steps Reaction - N-demethylation; cysteine conjugation |
AP26113
|
[1] |
|
Cytochrome P450 2C8 (CYP2C8)
|
DME0018
|
| Oxidation - N-Demethylation; Cysteine Conjugation |
Brigatinib
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Multi-steps Reaction - N-demethylation; cysteine conjugation |
AP26113
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - N-Demethylation; Cysteine Conjugation |
Brigatinib
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Brigatinib |
DR0228
|
Approved |
Anaplastic large cell lymphoma |
|
|
| AP26113 |
DR3362
|
Phase 2 |
Solid tumour/cancer |
|
|
| References |
| 1 |
Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
